What is Gaize?
Gaize specializes in the automated ocular testing for drugs, offering a sophisticated platform designed to detect impairment with over 98% accuracy. This technology is instrumental for businesses, including Fortune 500 companies, aiming to enforce fair drug policies while rigorously maintaining workplace safety. The company's innovative approach provides a quick and effective means to identify impairment, thereby mitigating risks associated with substance use in professional environments.
How much funding has Gaize raised?
Gaize has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2022): $1.2M with participation from Fritz Lanman
What's next for Gaize?
The recent major strategic investment signals Gaize's transition into a scaling phase, likely aimed at expanding its market reach and further developing its proprietary impairment detection technology. This backing will probably fuel advancements in its automated ocular testing capabilities and bolster its efforts to serve a broader range of safety-sensitive businesses. Gaize's trajectory suggests a continued focus on enhancing workplace safety through accurate and reliable drug impairment detection.
See full Gaize company page
